Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • Nora AI
  • About Us
    • Our Coverage
    • Team
Third party research

Vitrolife: Improved sales growth in Q3e - ABG

Vitrolife

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Sales growth of +7.8% and 20% EBIT margin in Q3e
EBITDA '24e-'26e revised down 1.4-1.8%
Q3'24 results due 24 October


Q3'24 expectations

We expect to see a pick-up in organic sales growth but some margin pressure in Q3. We forecast +7.8% organic growth for Vitrolife driven by 11% growth in Consumables, 4% growth in Technology, and a return to positive growth in Genetics of 6% in Q3, after several quarters with negative sales growth, mainly related to the US market. In total, we forecast Q3 sales of SEK 894.1m and EBIT of SEK 178.9m for a margin of 20.0%, down from 21.1% (adj EBIT in Q3'23), due to higher opex. Historically, selling expenses have been sequentially lower in Q3 vs Q2 for seasonality reasons, but this year we expect selling expenses to increase sequentially from Q2 into Q3 as management has been clear that they want to make investments in the organisation and also invest more in R&D, for future growth.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.